CSPC Innovation Pharmaceutical (SHE:300765) recorded a 98% decline in attributable profit in the third quarter to 2.3 million yuan from 116.9 million yuan a year prior, a Wednesday bourse filing by parent CSPC Pharmaceutical (HKG:1093) said.
Earnings per share were 0.002 yuan in the quarter, down from 0.0838 yuan in the corresponding period of last year.
The pharmaceutical company's revenue declined by 14% to 507.1 million yuan in the three months ended Sept. 30 from 592.9 million yuan in the year-ago period.
For the nine months ended Sept. 30, attributable profit and revenue plummeted 64% and 24% to 139.3 million yuan and 1.48 billion yuan, respectively.
Shares of CSPC Innovation Pharmaceutical closed 2% higher on Wednesday, while those of CSPC Pharmaceutical closed over 1% lower.
Price (HKD): $31.23, Change: $+0.61, Percent Change: +1.99%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。